peptide retatrutide Analog GLP-3RT Research Retatrutide Peptide | Research Peptide

Research presented at the European Congress on Obesity in 2024, for instance, found that people who gradually reduced their dose to zero (over an average of nine weeks) maintained a stable body weight in the first 26 weeks after tapering

In 2025, Ozempic was approved by the US Food and Drug Administration (FDA) to reduce the risk of worsening kidney disease and kidney failure in people with type 2 diabetes

A.MercierN

Tirzepatide (dual GLP-1/GIP receptor agonist): In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15 mg) achieved approximately 22.5% body weight reduction at 72 weeks

Standing against a wall with shoes off and looking straight ahead gives the most accurate result

Side effects About 50% of users reported nausea and one-third reported diarrhea in RANDs survey